Cargando…

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells

Androgen receptor (AR) signaling is fundamental to prostate cancer (PC) progression, and hence, androgen deprivation therapy (ADT) remains a mainstay of treatment. However, augmented AR signaling via both full length AR (AR-FL) and constitutively active AR splice variants, especially AR-V7, is assoc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khurana, Namrata, Chandra, Partha K., Kim, Hogyoung, Abdel-Mageed, Asim B., Mondal, Debasis, Sikka, Suresh C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022272/ https://www.ncbi.nlm.nih.gov/pubmed/31940946 http://dx.doi.org/10.3390/antiox9010068

Ejemplares similares

Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer
por: Khurana, Namrata, et al.
Publicado: (2017)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

Nrf1 and Nrf2 Transcription Factors Regulate Androgen Receptor Transactivation in Prostate Cancer Cells
por: Schultz, Michelle A., et al.
Publicado: (2014)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

The Nrf1 and Nrf2 Balance in Oxidative Stress Regulation and Androgen Signaling in Prostate Cancer Cells
por: Schultz, Michelle A., et al.
Publicado: (2010)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

Latent HIV-Exosomes Induce Mitochondrial Hyperfusion Due to Loss of Phosphorylated Dynamin-Related Protein 1 in Brain Endothelium
por: Chandra, Partha K., et al.
Publicado: (2021)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

Estradiol-ERβ2 signaling axis confers growth and migration of CRPC cells through TMPRSS2-ETV5 gene fusion
por: Kim, Hogyoung, et al.
Publicado: (2016)

Targeting Crosstalk between Nrf-2, NF-κB and Androgen Receptor Signaling in Prostate Cancer
por: Khurana, Namrata, et al.
Publicado: (2018)

Interplay Between SOX9, Wnt/β-Catenin and Androgen Receptor Signaling in Castration-Resistant Prostate Cancer
por: Khurana, Namrata, et al.
Publicado: (2019)

Mesenchymal stem cells are attracted to latent HIV-1-infected cells and enable virus reactivation via a non-canonical PI3K-NFκB signaling pathway
por: Chandra, Partha K., et al.
Publicado: (2018)

Therapeutic effects of C-28 methyl ester of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO-Me; bardoxolone methyl) on radiation-induced lung inflammation and fibrosis in mice
por: Wang, Yan-Yang, et al.
Publicado: (2015)

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
por: Ball, Michael S., et al.
Publicado: (2016)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

Racial Differences in Androgen Receptor (AR) and AR Splice Variants (AR-SVs) Expression in Treatment-Naïve Androgen-Dependent Prostate Cancer
por: Khan, Farhan, et al.
Publicado: (2023)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer
por: Ball, Michael S., et al.
Publicado: (2020)

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages
por: Torres, Gretel M., et al.
Publicado: (2022)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Saracatinib synergizes with enzalutamide to downregulate AR activity in CRPC
por: White, Ralph E., et al.
Publicado: (2023)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me reveals USP7 as a novel target in ovarian cancer cells
por: Qin, Dongjun, et al.
Publicado: (2016)

CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells
por: Chaudhari, Namrata, et al.
Publicado: (2017)

Regulation of androgen receptor splice variant AR3 by PCGEM1
por: Zhang, Ziqiang, et al.
Publicado: (2016)

Plasma AR Copy Number Changes and Outcome to Abiraterone and Enzalutamide
por: Gurioli, Giorgia, et al.
Publicado: (2020)

Molecular mechanisms of penile traction for penile rehabilitation in a bilateral cavernous nerve crush injury rat model
por: Dick, Brian, et al.
Publicado: (2023)

Antioxidants in Kidney Diseases: The Impact of Bardoxolone Methyl
por: Rojas-Rivera, Jorge, et al.
Publicado: (2012)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
por: El-Ashmawy, Mariam, et al.
Publicado: (2014)

Anticholestatic Effect of Bardoxolone Methyl on Hepatic Ischemia-reperfusion Injury in Rats
por: Kim, Joohyun, et al.
Publicado: (2020)

High-throughput screening identified selective inhibitors of exosome biogenesis and secretion: A drug repurposing strategy for advanced cancer
por: Datta, Amrita, et al.
Publicado: (2018)

Androgen receptor splice variants circumvent AR blockade by microtubule-targeting agents
por: Zhang, Guanyi, et al.
Publicado: (2015)

A noncanonical AR addiction drives enzalutamide resistance in prostate cancer
por: He, Yundong, et al.
Publicado: (2021)

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014)

Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
por: Qin, Dong-Jun, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_2apcdtodrkr75ee5120eer2mcq